Bocidelpar

CAS No. 2095128-20-2

Bocidelpar( —— )

Catalog No. M28225 CAS No. 2095128-20-2

Bocidelpar is a modulator of PPARδ with an EC50 of 7.80 nM and improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy muscle cells.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 278 In Stock
5MG 275 In Stock
10MG 411 In Stock
25MG 743 In Stock
50MG 1088 In Stock
100MG 1516 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Bocidelpar
  • Note
    Research use only, not for human use.
  • Brief Description
    Bocidelpar is a modulator of PPARδ with an EC50 of 7.80 nM and improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy muscle cells.
  • Description
    Bocidelpar is a modulator of PPARδ with an EC50 of 7.80 nM and improves mitochondrial biogenesis and function in Duchenne Muscular Dystrophy muscle cells.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    PPAR
  • Recptor
    Potassium Channel
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2095128-20-2
  • Formula Weight
    460.49
  • Molecular Formula
    C25H27F3N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 250 mg/mL (542.90 mM)
  • SMILES
    C[C@H](CCCOc1c(Cn2c(-c3ccc(C(F)(F)F)cc3)ncc2C)cccc1)CC(O)=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Su Z, et al. Novel cell-free high-throughput screening method for pharmacological tools targeting K+ channels. Proc Natl Acad Sci U S A. 2016;113(20):5748-5753.
molnova catalog
related products
  • Seladelpar

    A potent, selective, orally bioavailable PPARδ agonist for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).

  • JW55

    JW 55 is an inhibitor of the PARP domain of tankyrase 1 and 2 (TNKS1/2). JW55 decreased auto-PARsylation of TNKS1/2 in vitro with IC50 values of 1.9 uM and 830 nM respectively.

  • Furegrelate sodium

    Furegelate sodium is a selective thromboxane synthase inhibitor with oral activity.